Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTTR

Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis

Ritter Pharmaceuticals logo

About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)

Key Stats

Today's Range
$1.25
$1.34
50-Day Range
$0.45
$4.09
52-Week Range
$0.15
$1.27
Volume
28,860 shs
Average Volume
14.23 million shs
Market Capitalization
$61.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RTTR Stock News Headlines

Dr. John D. Ritter
Real reason Trump banning Chinese models
President Trump's administration is drafting a ban on Chinese-made components used inside American AI data centers - not chips, but a small, overlooked part that moves data through every facility. The move stems from a new economic doctrine crafted by a controversial Silicon Valley CEO, one already reshaping which companies are considered safe investments. Analysts Porter Stansberry and Luke Lango break down the full story and the shifts investors should watch.tc pixel
Kristen Ritter
Dr. Harold K. Ritter
Denver Business Journal welcomes new tech reporter
See More Headlines

RTTR Stock Analysis - Frequently Asked Questions

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01.

Ritter Pharmaceuticals shares reverse split on the morning of Friday, March 23rd 2018.The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Ritter Pharmaceuticals (RTTR) raised $20 million in an initial public offering (IPO) on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ritter Pharmaceuticals investors own include Chipotle Mexican Grill (CMG), APA (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA) and Hudson Technologies (HDSN).

Company Calendar

Last Earnings
5/01/2020
Today
8/06/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Software
Sub-Industry
Application Software
Current Symbol
NASDAQ:RTTR
CIK
1460702
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.13 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-162.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.67
Quick Ratio
3.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
13.40

Miscellaneous

Outstanding Shares
46,153,000
Free Float
N/A
Market Cap
$61.85 million
Optionable
Not Optionable
Beta
-0.43
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:RTTR) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners